Hopewell Therapeutics is advancing its leading edge tissue-targeted Lipid Nanoparticle (ttLNP) technology to discover, synthesize and develop the next generation of tissue-targeted LNPs. We are a purpose-driven team, working together to bring genomic medicines to patients with high unmet medical needs.

Hopewell Therapeutics Announces $25 Million Seed Financing to Advance Next Generation Lipid Nanoparticles for Targeted Delivery of Genomic Medicines